A potential role for the CDH13/CDH15 gene in repeat revascularization after first percutaneous coronary intervention

References

• 1. Li J, Li X, Wang Q et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet 385, 441–451 (2015).
  MedlineGoogle Scholar
• 2. Weintraub WS, Grau-Sepulveda MV, Weiss JM et al. Prediction of long-term mortality after percutaneous coronary intervention in older adults results from the National Cardiovascular Data Registry. Circulation 125, 1501–1510 (2012).
  MedlineGoogle Scholar
• 3. Chen W-W, Gao R-L, Liu L-S et al. 2017-Cardiovascular disease report in China – outline. Chin. Circ. J. 33(1), 1–8 (2018).
  Google Scholar
• 4. Roiron C, Sanchez P, Bouzamondo A et al. Drug eluting stents: an updated meta-analysis of randomized controlled trials. Heart 92, 641–649 (2006).
  Medline CASGoogle Scholar
• 5. Authors/Task Force members, Windecker S, Kolh P et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 35(37), 2541–2619 (2014).
  MedlineGoogle Scholar
• 6. Jukema JW, Verschuren JJ, Ahmed TA et al. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat. Rev. Cardiol. 9, 53–62 (2012).
  CASGoogle Scholar
• 7. Sampietro ML, Pons D, de Knijff P, Slagboom PE, Zwinderman A, Jukema JW. A genome wide association analysis in the GENDER study. Neth. Heart J. 17(6), 262–264 (2009).
  Medline CASGoogle Scholar
• 8. Miao HW, Gong H. Association of ACE insertion or deletion polymorphisms with the risk of coronary restenosis after percutaneous coronary intervention: a meta-analysis. J. Renin Angiotensin Aldosterone Syst. 16(4), 844–850 (2015).
  Medline CASGoogle Scholar
• 9. Ma W, Liang Y, Zhu J et al. Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting. Atherosclerosis 251, 305–310 (2016).
  Medline CASGoogle Scholar
• 10. Verschuren JJ, Sampietro ML, Pons D et al. Matrix metalloproteinases 2 and 3 gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention: is there still room for determining genetic variation of MMPs for assessment of an increased risk of restenosis? Dis. Markers 29(5), 265–273 (2010).
  Medline CASGoogle Scholar
• 11. Schulz S, Sibbing D, Braun S et al. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. Am. Heart J. 160(2), 355–361 (2010).
  Medline CASGoogle Scholar
• 12. Howie B, Fuchsberger C, Stephens M et al. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet. 44(8), 955–959 (2012).
  Medline CASGoogle Scholar
• 13. 1000 Genomes Project Consortium, Auton A, Brooks LD et al. A global reference for human genetic variation. Nature 526(7571), 68–74 (2015).
  MedlineGoogle Scholar
• 14. GTEx. www.gtexportal.org/home/gene/
  Google Scholar
• 15. Verschuren JJ, Trompet S, Sampietro ML et al. Pathway analysis using genome-wide association study data for coronary restenosis – a potential role for the PARVB gene. PLoS ONE 8(8), e70676 (2013).
  Medline CASGoogle Scholar
• 16. Bhalla K, Luo Y, Buchan T et al. Alterations in CDH15 and KIRREL3 in patients with mild to severe intellectual disability. Am. J. Hum. Genet. 83(6), 703–713 (2008).
  Medline CASGoogle Scholar
• 17. Frismantiene A, Pfaff D, Frachet A et al. Regulation of contractile signaling and matrix remodeling by T-cadherin in vascular smooth muscle cells: constitutive and insulin-dependent effects. Cell. Signal. 26(9), 1897–908 (2014).
  Medline CASGoogle Scholar
• 18. Takeuchi T, Adachi Y, Ohtsuki Y et al. Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease. Med. Mol. Morphol. 40(3), 115–120 (2007).
  Medline CASGoogle Scholar
• 19. Org E, Eyheramendy S, Juhanson P et al. Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Hum. Mol. Genet. 18(12), 2288–2296 (2009).
  Medline CASGoogle Scholar
• 20. Chung CM, Lin TH, Chen JW et al. A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardiometabolic outcomes. Diabetes 60(9), 2417–2423 (2011).
  Medline CASGoogle Scholar
• 21. Gao H, Kim YM, Chen P et al. Genetic variation in CDH13 is associated with lower plasma adiponectin levels but greater adiponectin sensitivity in east Asian populations. Diabetes 62(12), 4277–4283 (2013).
  Medline CASGoogle Scholar
• 22. de Maat MP, Jukema JW, Ye S et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am. J. Cardiol. 83(6), 852–856 (1999).
  Medline CASGoogle Scholar
• 23. Humphries S, Bauters C, Meirhaeghe A et al. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur. Heart J. 23(9), 721–725 (2002).
  Medline CASGoogle Scholar
• 24. Hoppmann P, Koch W, Schomig A et al. The 5A/6Apolymorphismofthestromelysin-1geneandrestenosis after percutaneous coronary interventions. Eur. Heart J. 25, 335–341 (2004).
  Medline CASGoogle Scholar
• 25. Verschuren JJ, Sampietro ML, Pons D et al. Matrix metalloproteinases 2 and 3 gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention: is there still room for determining genetic variation of MMPs for assessment of an increased risk of restenosis? Dis. Markers 29(5), 265–273 (2010).
  Medline CASGoogle Scholar
• 26. Giustino G, Baber U, Sartori S et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 65(13), 1298–1310 (2015).
  Medline CASGoogle Scholar